Evec Inc.
Hokkaido, JP· latest recorded location
Evec Inc. is named on 4 US grants and 9 published applications in this corpus. Its most frequent classification is C07K (Peptides).
- Granted patents
- 4
- Published applications
- 9
- Inventors
- 19
- Granted in 2026 so far
- 0
- Most recent grant
- 24 Jan 2017
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 1 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 0 | 1 |
| 2013 | 1 | 0 |
| 2014 | 1 | 1 |
| 2015 | 0 | 3 |
| 2016 | 0 | 0 |
| 2017 | 1 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 0 |
| 2025 | 0 | 1 |
By publication year.
Technology areas
Share of 13 documents
Recent patents
- Humanized anti-HMGB1 antibody or antigen-binding fragment thereof24 Jan 2017US 9,550,825 B2
- Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same25 Mar 2014US 8,679,502 B2
- Monoclonal antibody capable of binding to specific discontinuous epitope occurring in AD1 region of human cytomegalovirus GB glycoprotein, and antigen-binding fragment thereof23 Jul 2013US 8,492,529 B2
- Human monoclonal antibody binding to hGM-CSF and its antigen binding portion3 May 2011US 7,935,795 B2
- Human neutralizing antibody against sars-cov-2 having breadth to variant strains, and antigen-binding fragment thereof27 Mar 2025US 2025/0101085 A1
- Humanized antl-hmgb1 antibody or antigen-binding fragment thereof17 Dec 2015US 2015/0361164 A1
- Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof12 Nov 2015US 2015/0322137 A1
- Human antibody specific to toxin produced from clostridium difficile, or antigen-binding fragment thereof17 Sep 2015US 2015/0259402 A1
- Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same24 Jul 2014US 2014/0205611 A1
Most cited
By later US patents